Murphy; Leon

Patent Applications and Registrations

Patent applications and USPTO patent grants for Murphy; Leon.The latest application filed is for "treatment of cancer using humanized anti-bcma chimeric antigen receptor".

Company Profile

15.17.45

Murphy; Leon - Cambridge MA
Murphy; Leon - US
Murphy; Leon - Brookline MA US
Murphy; Leon - Newton MA
Murphy; Leon - Allston MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment Of Cancer Using Humanized Anti-bcma Chimeric Antigen Receptor App 20220064316 - Brogdon; Jennifer ; et al.	2022-03-03
Anti-BCMA chimeric antigen receptor Grant 11,084,880 - Brogdon , et al. August 10, 2	2021-08-10
Biomarkers Predictive Of Therapeutic Responsiveness To Chimeric Antigen Receptor Therapy And Uses Thereof App 20210172020 - Bedoya; Felipe ; et al.	2021-06-10
Pharmaceutical Combination Of Everolimus With Dactolisib App 20210030741 - Glass; David ; et al.	2021-02-04
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20210002377 - Brogdon; Jennifer ; et al.	2021-01-07
Methods For B Cell Preconditioning In Car Therapy App 20200339651 - Brogdon; Jennifer ; et al.	2020-10-29
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof Grant 10,774,388 - Bedoya , et al. Sept	2020-09-15
Treatment Of Cancer Using A Cll-1 Chimeric Antigen Receptor App 20200215171 - Brogdon; Jennifer ; et al.	2020-07-09
Treatment of cancer using a CD123 chimeric antigen receptor Grant 10,703,819 - Brogdon , et al.	2020-07-07
Pharmaceutical combination of everolimus with dactolisib Grant 10,576,076 - Glass , et al.	2020-03-03
Treatment of cancer using a CLL-1 chimeric antigen receptor Grant 10,568,947 - Brogdon , et al. Feb	2020-02-25
Low, Immune Enhancing, Dose Mtor Inhibitors And Uses Thereof App 20200054742 - Mannick; Joan ; et al.	2020-02-20
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20190388471 - June; Carl H. ; et al.	2019-12-26
Regulatable Chimeric Antigen Receptor App 20190263914 - Brogdon; Jennifer ; et al.	2019-08-29
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor Grant 10,357,514 - June , et al. July 23, 2	2019-07-23
Treatment Of Cancer Using 5 Humanized Anti-bcma Chimeric Antigen Receptor App 20190153061 - Brogdon; Jennifer ; et al.	2019-05-23
Low, immune enhancing, dose MTOR inhibitors and uses thereof Grant 10,286,069 - Mannick , et al.	2019-05-14
Regulatable chimeric antigen receptor Grant 10,287,354 - Brogdon , et al.	2019-05-14
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Grant 10,174,095 - Brogdon , et al. J	2019-01-08
Low, Immune Enhancing, Dose Mtor Inhibitors And Uses Thereof App 20180369370 - MANNICK; Joan ; et al.	2018-12-27
Methods For B Cell Preconditioning In Car Therapy App 20180334490 - Brogdon; Jennifer ; et al.	2018-11-22
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20180312595 - Brogdon; Jennifer ; et al.	2018-11-01
Pharmaceutical Combination Of Everolimus With Dactolisib App 20180289694 - Glass; David ; et al.	2018-10-11
Low, immune enhancing, dose mtor inhibitors and uses thereof Grant 10,004,803 - Mannick , et al. June 26, 2	2018-06-26
Phosphoglycerate Kinase 1 (pgk) Promoters And Methods Of Use For Expressing Chimeric Antigen Receptor App 20180118834 - Brogdon; Jennifer ; et al.	2018-05-03
Treatment of cancer using a CD123 chimeric antigen receptor Grant 9,815,901 - Brogdon , et al. November 14, 2	2017-11-14
Biomarkers Predictive Of Therapeutic Responsiveness To Chimeric Antigen Receptor Therapy And Uses Thereof App 20170306416 - Bedoya; Felipe ; et al.	2017-10-26
Low, Immune Enhancing, Dose Mtor Inhibitors And Uses Thereof App 20170281753 - MANNICK; Joan ; et al.	2017-10-05
Combinations Of Low, Immune Enhancing, Doses Of Mtor Inhibitors And Cars App 20170274014 - Brogdon; Jennifer ; et al.	2017-09-28
Regulatable Chimeric Antigen Receptor App 20160311907 - Brogdon; Jennifer ; et al.	2016-10-27
Imidazoquinolines as dual lipid kinase and mTOR inhibitors Grant 9,370,508 - Garcia-Echeverria , et al. June 21, 2	2016-06-21
Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases Grant 9,358,236 - Murphy , et al. June 7, 2	2016-06-07
Treatment Of Cancer Using A Cd33 Chimeric Antigen Receptor App 20160096892 - Brogdon; Jennifer ; et al.	2016-04-07
Treatment Of Cancer Using A Cd123 Chimeric Antigen Receptor App 20160068601 - Brogdon; Jennifer ; et al.	2016-03-10
Treatment Of Cancer Using A Cll-1 Chimeric Antigen Receptor App 20160051651 - Brogdon; Jennifer ; et al.	2016-02-25
Treatment Of Cancer Using Humanized Anti-bcma Chimeric Antigen Receptor App 20160046724 - Brogdon; Jennifer ; et al.	2016-02-18
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20150283178 - June; Carl H. ; et al.	2015-10-08
Low, Immune Enhancing, Dose Mtor Inhibitors And Uses Thereof App 20150140036 - Mannick; Joan ; et al.	2015-05-21
Combinations of Therapeutic Agents for use in the Treatment of Neurodegenerative Diseases App 20130331388 - Murphy; Leon ; et al.	2013-12-12
Pharmaceutical Combinations App 20130178479 - Chen; Yan ; et al.	2013-07-11
IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS App 20100105696 - Garcia-Echeverria; Carlos ; et al.	2010-04-29
Compositions and Methods for Modulating mTOR Signaling App 20090258929 - Finan; Peter ; et al.	2009-10-15
Methods And Reagents For The Treatment Of Apoptosis-related Disorders App 20070173472 - MacKeigan; Jeff ; et al.	2007-07-26

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.